Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objective: Panic disorder is characterized by recurrent panic attacks, persistent concerns about additional attacks, and worry about the implications of the attack or significant changes in behavior related to the attacks. We examined the efficacy of 24-week naturalistic, open-label escitalopram treatment in terms of the response and remission rates and functional disability in 119 adult Korean patients with panic disorder from 6 clinical centers in South Korea. Methods: Clinical severity and functional impairment were assessed at baseline and at 4, 12, and 24 weeks after the treatment using the Panic Disorder Severity Scale and Sheehan Disability Scale. Ninety-six patients (80.7%) showed a treatment response,and 87 patients (73.1%) had attained remission after 24 weeks of escitalopram treatment. Results: Continuous improvement in the Panic Disorder Severity Scale and Sheehan Disability Scale scores was found over the 24 weeks of treatment. Conclusion: These findings suggest that escitalopram treatment is very effective for panic disorder in terms of both response and remission rates and that long-term pharmacotherapy with escitalopram continuously improved panic symptoms and functional disability in Korean patients with panic disorder.
Abstract
Objective: Panic disorder is characterized by recurrent panic attacks, persistent concerns about additional attacks, and worry about the implications of the attack or significant changes in behavior related to the attacks. We examined the efficacy of 24-week naturalistic, open-label escitalopram treatment in terms of the response and remission rates and functional disability in 119 adult Korean patients with panic disorder from 6 clinical centers in South Korea. Methods: Clinical severity and functional impairment were assessed at baseline and at 4, 12, and 24 weeks after the treatment using the Panic Disorder Severity Scale and Sheehan Disability Scale. Ninety-six patients (80.7%) showed a treatment response,and 87 patients (73.1%) had attained remission after 24 weeks of escitalopram treatment. Results: Continuous improvement in the Panic Disorder Severity Scale and Sheehan Disability Scale scores was found over the 24 weeks of treatment. Conclusion: These findings suggest that escitalopram treatment is very effective for panic disorder in terms of both response and remission rates and that long-term pharmacotherapy with escitalopram continuously improved panic symptoms and functional disability in Korean patients with panic disorder.
참고문헌 (22)
- Kessler RC, "The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 63, pp.415~424 (2006)
- Kroenke K, "Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection", Ann Intern Med, 146, pp.317~325 (2007)
- Noyes R Jr, "Outcome of panic disorder. Relationship to diagnostic subtypes and comorbidity", Arch Gen Psychiatry, 47, pp.809~818 (1990)
- Wittchen HU, "Epidemiology of panic disorder: progress and unresolved issues", J Psychiatr Res, 27(Suppl 1), pp.47~68 (1993)
- Cramer V, "Quality of life and anxiety disorders: a population study", J Nerv Ment Dis, 193, pp.196~202 (2005)
- Bandelow B, "Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo", Pharmacopsychiatry, 40, pp.152~156 (2007)
- Markowitz JS, "Quality of life in panic disorder", Arch Gen Psychiatry, 46, pp.984~992 (1989)
- Weissman MM., "Panic disorder: impact on quality of life", J Clin Psychiatry, 52(Suppl), pp.6~8 (1991)
- Ormel J, "Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care", JAMA, 272, pp.1741~1748 (1994)
- Shear MK, "Standardized assessment for panic disorder research. A conference report", Arch Gen Psychiatry, 51, pp.346~354 (1994)
- Stahl SM, "Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 64, pp.1322~1327 (2003)
- Rampello L, "New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram", J Clin Psychopharmacol, 26, pp.67~70 (2006)
- Bandelow B, "Treatment-resistant panic disorder", CNS Spectr, 9, pp.725~739 (2004)
- Sheehan DV, "The Anxiety Disease" (1983), Scribner's
- Shear MK, "The road to recovery in panic disorder: response, remission, and relapse", J Clin Psychiatry, 59(Suppl 8), pp.4~8 (1998)
- Furukawa TA, "Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale", Depress Anxiety, 26, pp.922~929 (2009)
- Liebowitz MR, "A double-blind, placebo-controlled, parallel-group, flexibledose study of venlafaxine extended release capsules in adult outpatients with panic disorder", J Clin Psychiatry, 70, pp.550~561 (2009)
- Mochcovitch MD, "Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies", Expert Rev Neurother, 10, pp.1285~1293 (2010)
- Ballenger JC, "Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder", Am J Psychiatry, 155, pp.36~42 (1998)
- Pollack M, "A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder", Psychopharmacology, 194, pp.233~242 (2007)
- Sherbourne CD, "Functioning and well-being of patients with panic disorder", Am J Psychiatry, 153, pp.213~218 (1996)
- Asnis GM, "Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients", Psychiatry Res, 103, pp.1~14 (2001)